Why the study?
What is the pharmacological and clinical profile of valsartan in the treatment of hypertension and related diseases?
What is the pharmacological and clinical profile of valsartan in the treatment of hypertension and related diseases?
This review summarizes the pharmacological properties, efficacy, and tolerability of valsartan for the management of hypertension and prevention of related organ damage.
Synthesizes long-term valsartan data for hypertension; leaves open need for updated comparative trials with newer agents.
The development of angiotensin II (Ang II) receptor antagonists is one of the latest advances in the pharmacological treatment of hypertension and other related diseases. Since the antagonism of angiotensin biological activity has been shown to represent a potent way to favorably affect systemic hypertension, its use is becoming more and more widespread among clinical practice. Besides the originally developed inhibitors of angiotensin II converting enzyme, today molecules that are effective in selectively blocking the type I angiotensin II receptor are available. In this report we describe the main characteristics of one of these compounds, the angiotensin receptor antagonist valsartan, in terms of pharmacological profile as well as efficacy and tolerability. The main purpose is to provide a comprehensive description of the knowledge gained during several years of experimental and clinical studies that can be useful for guidance during the choice for treatment of hypertension, as well as to obtain other potential beneficial effects of this drug on progressive organ damage related to hypertension.
No takes yet. Share an insight, caveat, or question.
Andrea Remuzzi (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: